{"id":739,"date":"2024-08-12T22:04:34","date_gmt":"2024-08-12T14:04:34","guid":{"rendered":"https:\/\/flcube.com\/?p=739"},"modified":"2024-10-13T22:26:38","modified_gmt":"2024-10-13T14:26:38","slug":"tyk-medicines-inc-targets-hkd-506-3-million-in-hong-kong-ipo-for-drug-pipeline-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=739","title":{"rendered":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion"},"content":{"rendered":"\n<p>TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total of HKD 506.3 million (USD 64 million).<\/p>\n\n\n\n<p>Established in 2017, TYK Med has an impressive pipeline of 11 drugs, with key products being TY-9591, a third-generation EGFR inhibitor. TY-9591 is currently undergoing a Phase II study for EGFR mutant non-small cell lung cancer (NSCLC) with brain metastasis and a Phase III study for EGFR L858R nutant locally advanced or metastatic NSCLC. Additionally, the company is developing TY-302. It is planned that 70% of the proceeds from the IPO will be allocated to the research, development, and commercialization of TY-9591.<\/p>\n\n\n\n<p>In 2022, TYK Med recorded revenues of RMB 44 million and reported a loss of RMB 312 million, with income primarily sourced from a licensing agreement with Livzon Pharma. For the first quarter of 2024, the company&#8217;s research and development expenses were RMB 64.7 million, with net losses amounting to RMB 108 million. As of the end of the first quarter, TYK Med&#8217;s cash and cash equivalents were reported at RMB 77.20 million.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[72,395],"class_list":["post-739","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ipo","tag-tyk-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total of HKD 506.3 million (USD 64 million).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=739\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=739\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-12T14:04:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T14:26:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion\",\"datePublished\":\"2024-08-12T14:04:34+00:00\",\"dateModified\":\"2024-10-13T14:26:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"IPO\",\"TYK Medicines\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=739#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=739\",\"name\":\"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-12T14:04:34+00:00\",\"dateModified\":\"2024-10-13T14:26:38+00:00\",\"description\":\"TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total of HKD 506.3 million (USD 64 million).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=739\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=739#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total of HKD 506.3 million (USD 64 million).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=739","og_locale":"en_US","og_type":"article","og_title":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=739","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-12T14:04:34+00:00","article_modified_time":"2024-10-13T14:26:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=739#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=739"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion","datePublished":"2024-08-12T14:04:34+00:00","dateModified":"2024-10-13T14:26:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=739"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["IPO","TYK Medicines"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=739#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=739","url":"https:\/\/flcube.com\/?p=739","name":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-12T14:04:34+00:00","dateModified":"2024-10-13T14:26:38+00:00","description":"TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial public offering (IPO) on the Hong Kong Stock Exchange (HKSE). The company plans to issue 47,880,000 shares, priced at HKD 12.1 each, under the ticker symbol 02410. This IPO is expected to raise a total of HKD 506.3 million (USD 64 million).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=739#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=739"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=739#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=739"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/739\/revisions"}],"predecessor-version":[{"id":6234,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/739\/revisions\/6234"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}